FAR HILLS, N.J.–(BUSINESS WIRE)– #AMD–Samsara Vision Announces First Pseudophakic Surgery in the PERSPECTIVE Clinical Trial to evaluate SING IMT in Patients with Previous Cataract Surgery
Category: News
Eye Health America Announces Jay Burkett as Chief Executive Officer; Mary Lou Parisi as Chief Growth Officer
GREENVILLE, S.C.–(BUSINESS WIRE)–Eye Health America announced today Jay Burkett has been named Chief Executive Officer. Mary Lou Parisi, co-CEO, was named Chief Growth Officer.
Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood,…
STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today highlighted commentary from numerous independent i…
STAAR Surgical Addresses Broadwood Partners’ Flawed, Misleading, and Misinformed Claims
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement with respect to the…
Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today announced that…
Long-Term Control of NMOSD With Ravulizumab
For neuromyelitis optica spectrum disorder, long-term follow-up with a second-generation complement inhibitor shows an unprecedented level of disease control at 3 years. Medscape Medical News
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the C…
Intravitreal Injection of Retinal Progenitor Cells Shows Promise in Preclinical Study for Diabetic Retinopathy
IRVINE, Calif.–(BUSINESS WIRE)–A new preclinical study titled “Intravitreal Transplantation of Retinal Progenitor Cells Improves Outcome Measures in a Rat Model of Diabetic Retinopathy” reports that retinal progenitor cells (RPCs) may provide both fu…
Mutation-Agnostic Gene Therapy May Restore Vision in RP
The MCO-010 vector uses surviving cells in the retina to produce a photosensitive protein that may help patients regain some vision despite a loss of typical photoreceptors. Medscape Medical News
Les troubles de la vision ne sont pas toujours évidents
OTTAWA, Ontario–(BUSINESS WIRE)–L’Association canadienne des optométristes (ACO) encourage les examens de la vue complets réguliers pour les enfants avec une nouvelle campagne.
Eye Issues Aren’t Always Obvious
OTTAWA, Ontario–(BUSINESS WIRE)–The Canadian Association of Optometrist (CAO) urges regular comprehensive eye exams for children with a new awareness campaign.
Les troubles de la vision ne sont pas toujours évidents
OTTAWA, Ontario–(BUSINESS WIRE)–L’Association canadienne des optométristes (ACO) encourage les examens de la vue complets réguliers pour les enfants avec une nouvelle campagne.
Terravet Real Estate Solutions Becomes Terramed Real Estate Solutions Amid Expansion Into High‑Need Medical Specialties
BALA CYNWYD, Pa.–(BUSINESS WIRE)–Terravet Real Estate Solutions rebrands as Terramed, expanding from veterinary into ophthalmology and fertility.
Lumata Health Improves Patient Adherence to Vision-Saving Treatments by Alleviating Barriers to Care
RALEIGH, N.C.–(BUSINESS WIRE)– #ContinuousCare–Lumata Health, the company focused on ending preventable blindness with continuous ophthalmic care for people facing chronic eye disease, today announced the results of its new research report, “Lumata’…
Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR
GENEVA & LAKE FOREST, Calif.–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the manufacturer of the Implantable Collamer® Lens (IC…
Ophthalmologists Often First to Spot Ocular Syphilis
Ocular syphilis is re-emerging in Europe and is often first detected by ophthalmologists, with acute placoid chorioretinitis being a common manifestation. Medscape News UK
GenSight Biologics Reports Interim Financial Results for the First Half of 2025
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
GenSight Biologics publie ses résultats financiers du premier semestre 2025
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladie…
Neurotech Granted Permanent J-Code (J3403) for ENCELTO™ (revakinagene taroretcel-lwey), Effective October 1, 2025
CUMBERLAND, R.I.–(BUSINESS WIRE)–Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has assig…